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additional graft engineering to confer a selective advantage, appear to
be required for the use of non-TBI–based regimens in LAD. These
data indicate that 200 cGy TBI is superior to 10 mg/kg busulfan as a
single agent for conditioning before HSCT for CLAD.
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NIEMANN-PICK TYPE B: SUCCESSFUL ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION WITH CORRECTION OF ENZYME LEVELS
Schneiderman, J., Thormann, K., Kletzel, M. Children’s Memorial
Hospital, Chicago, IL.
Niemann-Pick is an autosomal recessive lysosomal storage disorder
presenting in early childhood with a variety of symptoms, depending
on phenotype. Type B results from the lack of sphingomyelinase,
leading to pathological deposition of sphingomyelin and other lipids
in the monocyte/macrophage system. We present the case of an
18-month-old female with type B disease who underwent allogeneic
bone marrow transplantation from her HLA-identical sister.
C.S. was referred to our clinic at age 6 months due to spleno-
megaly and thrombocytopenia. Bone marrow aspirate revealed the
presence of multiple storage cells. Sphingomyelinase levels in the
peripheral leukocytes were  1% of normal. Ophthalmologic ex-
amination revealed the presence of “cherry red” spots bilaterally. A
skin biopsy was performed and conﬁrmed the absence of sphingo-
myelinase activity in cultured ﬁbroblasts, conﬁrming the diagnosis.
Due to progressive disease, we proceeded with stem cell trans-
plantation. The patient received thiotepa 300 mg/m2/day for 3
days and cyclophosphamide (CTX) 1500 mg/m2/day for 3 days,
followed by 1.5  108 mononuclear cells (MNCs)/kg. Although
initial signs of engraftment were noted by day 30, evidence of
autologous recovery was found by RFLP on day 73. Sphingomy-
elinase levels were  1% of normal. A second transplantation was
therefore performed. Conditioning consisted of fTBI (1200 cGy in
150-cGy fractions) and CTX 60 mg/m2/day for 3 days. Cell dose
was 5.9  108 MNC/kg. On day 31, full donor engraftment (
95%) was established by RFLP. Sphingomyelinase levels in pe-
ripheral leukocytes were 2.29 (normal, 0.75–3.5).
Eight years after transplant, engraftment has been durable, and
all subsequent sphingomyelinase levels have been normal. Liver
and spleen volumes were evaluated before and after transplantation
and have improved signiﬁcantly. The patient has extensive
cGVHD (chronic active hepatitis and extremity contractures), al-
though her Lansky performance is 90%.
Stem cell transplantation has been curative in patients with Hurl-
er’s syndrome, Niemann-Pick type A, and adrenoleukodystrophy.
Few patients with Niemann-Pick type B have received transplan-
tation as deﬁnitive therapy because of the lower incidence of
progressive neurologic sequellae. Our experience indicates that
stem cell transplantation for patients with Niemann-Pick type B is
feasible and curative. Engraftment may be a problem in these
patients due to inﬁltration of storage cells; an ablative regimen may
be required to overcome this problem.
Table 1.
Date
Splenic Volume
(cc)
Hepatic Volume
(cc)
6/20/95 271 742
2/1/96 460 1135
9/1/00 433 1109
9/17/02 339 844
240
DENDRITIC CELL AND T-CELL SUBSETS CORRELATE WITH THE DEVEL-
OPMENT AND SITE OF ACUTE GVHD FOLLOWING UNRELATED CORD
BLOOD TRANSPLANTATION IN CHILDREN: A MULTIVARIATE ANALYSIS
Szabolcs, P.1, Park, K.-D.1, Niedzwiecki, D.2, Sanders, L.2, Lee, Y.-A.1,
Marti, L.1, Reese, M.1, Kurtzberg, J.1 1Pediatric Bone Marrow Trans-
plantation, Duke University Medical Center, Durham, NC; 2Depart-
ment of Biostatistics, Duke University Medical Center, Durham, NC.
HLA-mismatched unrelated umbilical cord blood transplan-
tation (uUCBT) is a suitable option for those who lack HLA-
matched sibling donors. Despite the limited cytotoxicity and
cytokine production of UCB T cells, uUCBT can lead to sig-
niﬁcant aGVHD. We hypothesized that select features of T-cell
and dendritic cell (DC) reconstitution will correlate with the
development of aGVHD. Here we report on 106 prospectively
studied pediatric patients, all full donor chimera. Methods:
T-cell subsets, CD123/plamacytoid, and CD11c/myeloid
DCs were monitored on day 50 by 4-color surface and IC
FACS. Homeostatic T-cell proliferation, activation state, and
inducible cytokine secretion were all measured and tested for
correlation with aGVHD. Logistic regression models were cre-
ated for those variables that had a P value  .05 by the Wilcoxon
rank-sum test. Results: The mean age of the patients was 6.4
years; 65 (61%) are alive at a mean time of 39 months post-
transplantation. Survival is lower (26%; n  21) in patients who
developed aGVHD at grade III-IV versus those with grade 0-II
(73%; n  85) (P  .0001), whereas it is almost identical for
those with grade II-IV (n  52) versus 0-I (n  54). Of potential
confounders, only younger age/less weight carried a risk for
grade II-IV aGVHD, whereas for grade III-IV aGVHD, HLA
mismatch at 2–3 HLA alleles was the only risk factor (P  .008).
More patients with grade III-IV aGVHD experienced de novo
opportunistic infection (OI) impacting their survival (P 
.0001), whereas death due to OI was similar for those with grade
II-IV GVHD and those with grade 0-I GVHD. Noninfectious
mortality was similar regardless of GVHD grade (P  .75).
Table 1 presents immune parameters correlating with increased
risk for grade II-IV aGVHD. When OI was introduced as a
confounder in the Cox model, some variables correlating with
developing grade III-IV GVHD (eg, activated DR/CD4 T
cells) lost signiﬁcance; however, higher numbers of circulating
CD4 T cells secreting IL-2 and TNF remained signiﬁcant.
Additionally, those with fewer CD123 DCs in the circulation
(0.7/L) were at increased risk for grade III-IV aGVHD,
whereas those with more CD123 DCs (2.5/L) had only grade
0-I (P  .009). Patients with grade III-IV GVHD had more T
cells in cell cycle (27% Ki67 cells vs 16%; P  .04). In patients
with skin only grade II-IV GVHD elevated percentage of T
cells were circulating, expressing the skin-homing molecule
CLA (1.9% vs 0.1%; P  .05). Conclusion: Select features of
T-cell and DC reconstitution can identify those at risk for
GVHD.
Table 1. Univariate and Multivariate Analysis of Day 50 Immune
Proﬁle and the Risk for Developing Grade II–IV Acute GVHD
Variable
Median
Values in
Those
With
GVHD
Median
Values in
Those
Without
GVHD
p-Value
(Rank
Sum
Test)
p-Value
(Logistic
Regression)
%TNF secreting T
cells 18% 2% 0.0001 0.001
%CD8 T cells
secreting TNF 5.8% 0.6% 0.008 <0.03
%CD4 T cells
secreting TNF 22% 4% 0.0002 <0.002
% IL-2 secreting T
cells 17% 8% 0.0009 <0.005
% IL-2 secreting
CD4 T cells 31% 14% 0.007 <0.012
Confounders tested; age, gender, weight, CMV serology, HLA
mismatch, malignancy, TBI, presence of Opportunistic Infec-
tions (OI), infused total cell dose/kg, CD34 progenitor/kg,
CD3 T cell dose/kg.
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